The Effect of Oral Antiseptic Gargles on the Oral Cavity Microbiome

NCT ID: NCT03141554

Last Updated: 2017-06-06

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

PHASE4

Total Enrollment

12 participants

Study Classification

INTERVENTIONAL

Study Start Date

2017-05-05

Study Completion Date

2017-05-19

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

This study determines the effects of a single dose of different antiseptic mouth washes within the oral cavity, on the composition of the oral microbiome using next generation sequencing (NGS) techniques. Twelve healthy volunteers will receive all three test products in a randomized order to compare the effects of each mouth wash.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Disinfectants and oral antiseptics including PVP-I are known to kill microorganisms to a variable extent, at a variable range of time points. Microorganisms may be protected from disinfectants by production of thick masses of cells and extracellular materials, or biofilms. Moreover, antiseptics should not lead to dysbiosis after use. Dysbiosis is a negative change in the microbiome of a particular skin or mucosal region. The Human Microbiome project showed, that every area has a specific microbiota in which the human host lives with an abundance of commensal, synergistic, and potentially pathogenic microorganisms. Antiseptics with efficacy gaps and resistance may induce such dysbiosis, especially after prolonged use.

It is envisaged that twelve healthy volunteers will complete the study. Each healthy volunteer will rinse with the test product according to a developed protocol, between established wash out periods.

The ability of the test product (1% Betadine® PVP-I based mouth wash and gargle) compared to the reference products (0.2% Chlor-Rinse™ Chlorhexidine based mouth wash (No alcohol) and Normal saline gargle) to reduce resident and transient microflora will be assessed. The mouth wash products will also be assessed for their ability to maintain and/or restore balanced microflora.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Oral Health

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

SEQUENTIAL

12 healthy volunteers will be randomized into 3 arms with 3 different treatment sequences with 4 healthy volunteers in each arm.
Primary Study Purpose

PREVENTION

Blinding Strategy

SINGLE

Outcome Assessors

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Treatment Sequence Group 1

Treatment Sequence Group 1 = A -\> B -\> C

Treatment A = 1% Betadine® PVP-I based mouth wash and gargle

Treatment B = 0.2% Chlor-Rinse™ Chlorhexidine based mouth wash (no alcohol)

Treatment C = Normal saline gargle (lukewarm).

Group Type ACTIVE_COMPARATOR

1% Betadine® PVP-I based mouth wash and gargle,

Intervention Type DRUG

1% Betadine® PVP-I based mouth wash and gargle

0.2% Chlor-Rinse™ Chlorhexidine based mouth wash

Intervention Type DRUG

0.2% Chlor-Rinse™ Chlorhexidine based mouth wash

Normal saline gargle

Intervention Type DRUG

Normal saline gargle

Treatment Sequence Group 2

Treatment Sequence Group 2 = B -\> C -\> A

Treatment B = 0.2% Chlor-Rinse™ Chlorhexidine based mouth wash (no alcohol)

Treatment C = Normal saline gargle (lukewarm).

Treatment A = 1% Betadine® PVP-I based mouth wash and gargle

Group Type ACTIVE_COMPARATOR

1% Betadine® PVP-I based mouth wash and gargle,

Intervention Type DRUG

1% Betadine® PVP-I based mouth wash and gargle

0.2% Chlor-Rinse™ Chlorhexidine based mouth wash

Intervention Type DRUG

0.2% Chlor-Rinse™ Chlorhexidine based mouth wash

Normal saline gargle

Intervention Type DRUG

Normal saline gargle

Treatment Sequence Group 3

Treatment Sequence Group 3 = C -\> A -\> B

Treatment C = Normal saline gargle (lukewarm).

Treatment A = 1% Betadine® PVP-I based mouth wash and gargle

Treatment B = 0.2% Chlor-Rinse™ Chlorhexidine based mouth wash (no alcohol)

Group Type ACTIVE_COMPARATOR

1% Betadine® PVP-I based mouth wash and gargle,

Intervention Type DRUG

1% Betadine® PVP-I based mouth wash and gargle

0.2% Chlor-Rinse™ Chlorhexidine based mouth wash

Intervention Type DRUG

0.2% Chlor-Rinse™ Chlorhexidine based mouth wash

Normal saline gargle

Intervention Type DRUG

Normal saline gargle

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

1% Betadine® PVP-I based mouth wash and gargle,

1% Betadine® PVP-I based mouth wash and gargle

Intervention Type DRUG

0.2% Chlor-Rinse™ Chlorhexidine based mouth wash

0.2% Chlor-Rinse™ Chlorhexidine based mouth wash

Intervention Type DRUG

Normal saline gargle

Normal saline gargle

Intervention Type DRUG

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Male and female subjects 21 years and older,
* Not pregnant nor trying to conceive during the study period,
* Non-smoker, non-tobacco user (no chewing of tobacco or similar products),
* No systemic or topical oral antibiotic or antifungal in the past 2 months (from date of consent),
* No ongoing medication (e.g., immunosuppressive medication, no systemic or inhaled glucocorticoids),
* Prepared to use a toothpaste that does not any antimicrobials (Colgate Maximum Cavity Protection) for 2 days after providing consent and during the study,
* Prepared to refrain from using mouth washes/gargles or any other oral hygiene product for 2 days after providing consent and during the study,
* Good oral health (e.g., no visible bleeding, inflammation, oral ulcer or oral lesion, no need for dental treatment),
* Must have given written informed consent.

Exclusion Criteria

* Allergy or contraindication to any test product substance (active or excipients),
* Known hyperthyroidism,
* Consumption of alcoholic beverages 24 hours before test product administration on Day 0, Day 2, and Day 4,
* Wearing dental appliances (all types of braces, removable or fixed dentures, etc.),
* Minor ailments like cough, cold, upper respiratory tract infection(s), or oral ulcer(s),
* Unwillingness or inability to comply with the requirements of the protocol,
* Participation in any other drug, biologic, device, or clinical study or treatment with any investigational drug or approved therapy for investigational use within 30 days (or 5 half-lives, whichever is longer) prior to the screening visit.
Minimum Eligible Age

21 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

Yes

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Singapore Polytechnic (SP)

UNKNOWN

Sponsor Role collaborator

Mundipharma Manufacturing Pte Ltd.

INDUSTRY

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Responsibility Role SPONSOR

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

National University of Singapore Hospital

Singapore, , Singapore

Site Status

Countries

Review the countries where the study has at least one active or historical site.

Singapore

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

BTD16-SG-401

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.